JP2011502172A - ホルモンおよびステロイド用の経皮送達システム - Google Patents

ホルモンおよびステロイド用の経皮送達システム Download PDF

Info

Publication number
JP2011502172A
JP2011502172A JP2010532376A JP2010532376A JP2011502172A JP 2011502172 A JP2011502172 A JP 2011502172A JP 2010532376 A JP2010532376 A JP 2010532376A JP 2010532376 A JP2010532376 A JP 2010532376A JP 2011502172 A JP2011502172 A JP 2011502172A
Authority
JP
Japan
Prior art keywords
acetate
delivery system
transdermal delivery
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2010532376A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502172A5 (enExample
Inventor
ケリー・セティアワン
アダム・ワトキンソン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acrux DDS Pty Ltd
Original Assignee
Acrux DDS Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrux DDS Pty Ltd filed Critical Acrux DDS Pty Ltd
Publication of JP2011502172A publication Critical patent/JP2011502172A/ja
Publication of JP2011502172A5 publication Critical patent/JP2011502172A5/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M35/00—Devices for applying media, e.g. remedies, on the human body
    • A61M35/003—Portable hand-held applicators having means for dispensing or spreading integral media
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/16—Masculine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2010532376A 2007-11-02 2008-10-31 ホルモンおよびステロイド用の経皮送達システム Ceased JP2011502172A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98478707P 2007-11-02 2007-11-02
PCT/AU2008/001613 WO2009055859A1 (en) 2007-11-02 2008-10-31 Transdermal delivery system for hormones and steroids

Publications (2)

Publication Number Publication Date
JP2011502172A true JP2011502172A (ja) 2011-01-20
JP2011502172A5 JP2011502172A5 (enExample) 2011-12-08

Family

ID=40590452

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010532376A Ceased JP2011502172A (ja) 2007-11-02 2008-10-31 ホルモンおよびステロイド用の経皮送達システム
JP2010532377A Expired - Fee Related JP5737942B2 (ja) 2007-11-02 2008-10-31 経皮送達システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010532377A Expired - Fee Related JP5737942B2 (ja) 2007-11-02 2008-10-31 経皮送達システム

Country Status (17)

Country Link
US (5) US20100279988A1 (enExample)
EP (2) EP2214643B1 (enExample)
JP (2) JP2011502172A (enExample)
KR (2) KR101662186B1 (enExample)
CN (2) CN101883556B (enExample)
AU (2) AU2008318283B2 (enExample)
BR (2) BRPI0819235A2 (enExample)
CA (2) CA2704116A1 (enExample)
DK (2) DK2219603T3 (enExample)
EA (2) EA201000747A1 (enExample)
ES (2) ES2494853T3 (enExample)
MX (2) MX2010004788A (enExample)
NZ (2) NZ585033A (enExample)
PL (2) PL2214643T3 (enExample)
PT (2) PT2214643E (enExample)
WO (2) WO2009055859A1 (enExample)
ZA (1) ZA201003553B (enExample)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR068409A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Composiciones farmaceuticas, transdermicas sin alcohol
AR068408A1 (es) * 2007-09-14 2009-11-18 Drugtech Corp Pulverizacion de hormonas transdermicas
EA201000747A1 (ru) * 2007-11-02 2010-10-29 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
US20130253449A1 (en) * 2010-12-07 2013-09-26 Yutoku Pharmaceutical Industries Co., Ltd. Noradrenergic and specific serotonergic antidepressant-containing transdermal patch
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
JPWO2013183407A1 (ja) * 2012-06-05 2016-01-28 祐徳薬品工業株式会社 ミルタザピン含有経皮吸収型貼付製剤
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10201549B2 (en) * 2013-06-14 2019-02-12 Professional Compounding Centers Of America (Pcca) Testosterone combined with anastrozole injection solutions
US20150065426A1 (en) * 2013-08-27 2015-03-05 Professional Compounding Centers Of America Testosterone Booster Transdermal Compositions
CN111840246A (zh) * 2014-05-05 2020-10-30 艾尔建制药国际有限公司 用于抗孕激素的阴道递送的制剂和方法
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
EP3261645B1 (en) 2015-02-27 2021-04-28 Dechra Limited Stimulation of appetite, management of weight loss, and treatment of anorexia in dogs and cats
WO2016167545A1 (ko) * 2015-04-13 2016-10-20 주식회사 엘지생활건강 신경전달물질의 배출을 조절하는 성분이 포함된 용해성 마이크로니들
CN107427474A (zh) 2015-04-13 2017-12-01 株式会社Lg生活健康 含有调节神经递质释放的成分的可溶性微针
US20180125860A1 (en) * 2015-05-18 2018-05-10 Agile Therapeutics, Inc. Contraceptive Compositions and Methods for Improved Efficacy and Modulation of Side Effects
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10449201B2 (en) * 2015-08-17 2019-10-22 Alpha To Omega Pharmaceutical Consultants, Inc. Transdermal and/or topical delivery system comprising clobazam
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
WO2018031576A1 (en) * 2016-08-08 2018-02-15 Baucom Karan Y Hormone delivery system and method
US20200054649A1 (en) * 2016-11-17 2020-02-20 Cytoo Skeletal muscle hypertrophy inducers
KR102436756B1 (ko) * 2017-01-31 2022-08-29 신신제약 주식회사 비스테로이드계 소염진통제와 살리실산 유도체를 포함하는 경피흡수 제제
GB2560365B (en) 2017-03-09 2021-10-20 Brightwake Ltd Improvements relating to apparatus negative pressure wound therapy
CN107929268A (zh) * 2017-12-19 2018-04-20 郑州泰丰制药有限公司 一种含质子泵抑制剂药物的透皮贴剂及其制备方法
ES2983874T3 (es) * 2018-01-10 2024-10-25 Celista Pharmaceuticals Llc Pulverización transdérmica de testosterona con película
US10285998B1 (en) 2018-04-04 2019-05-14 The Menopause Method, Inc. Composition and method to aid in hormone replacement therapy
CN108703942B (zh) * 2018-04-23 2021-04-06 中山大学 载有纳米材料包裹保胎药物的微针给药系统及制备方法
EP3817731B1 (en) 2018-07-05 2025-09-03 Celista Pharmaceuticals Llc Testosterone and estradiol transdermal spray
CN110947088A (zh) * 2019-12-06 2020-04-03 广州新济薇娜生物科技有限公司 护眼组合贴片及其制备方法
KR102592892B1 (ko) 2021-03-12 2023-10-23 충남대학교산학협력단 데속시코르티코스테론 글루코사이드를 포함하는 당뇨병 예방 또는 치료용 조성물

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044347A1 (en) * 1999-02-01 2000-08-03 Cipla Limited Medicated stick composition
WO2006113242A2 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK534178A (da) 1977-12-16 1979-06-17 Interx Research Corp Anticholinerge midler med sektrtionshaemmende virkning
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4906475A (en) * 1988-02-16 1990-03-06 Paco Pharmaceutical Services Estradiol transdermal delivery system
JPH01308225A (ja) * 1988-06-03 1989-12-12 Nissan Chem Ind Ltd 外用医薬組成物
DE69007886T2 (de) * 1989-07-21 1994-11-17 Izhak Blank Östradiol enthaltende Mittel und Verfahren zur topischen Anwendung.
US5276079A (en) * 1991-11-15 1994-01-04 Minnesota Mining And Manufacturing Company Pressure-sensitive poly(n-vinyl lactam) adhesive composition and method for producing and using same
WO1994006452A1 (en) * 1992-09-21 1994-03-31 The Upjohn Company Sustained-release protein formulations
WO1994007478A1 (en) * 1992-10-06 1994-04-14 The Upjohn Company Topical pharmaceutical compositions
US6998138B2 (en) * 1996-02-19 2006-02-14 Acrux Dds Pty. Ltd. Topical delivery of anti-alopecia agents
US6929801B2 (en) * 1996-02-19 2005-08-16 Acrux Dds Pty Ltd Transdermal delivery of antiparkinson agents
US6916487B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of antiemetics
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US6923983B2 (en) * 1996-02-19 2005-08-02 Acrux Dds Pty Ltd Transdermal delivery of hormones
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
US7094422B2 (en) * 1996-02-19 2006-08-22 Acrux Dds Pty Ltd. Topical delivery of antifungal agents
RO121628B1 (ro) * 1999-02-05 2008-01-30 Cipla Limited Compoziţie medicinală, topică, pulverizabilă,dozator care o conţine, procedeu de realizare a dozatorului şi utilizarea compoziţiei menţionate
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
IL150289A0 (en) * 2000-01-19 2002-12-01 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine
CA2466425A1 (en) * 2001-11-09 2003-05-15 Qlt Inc. Photodynamic therapy for the treatment of hair loss
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
CA2489865C (en) * 2002-06-25 2012-05-08 Acrux Dds Pty Ltd Transdermal delivery rate control using amorphous pharmaceutical compositions
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
AUPS317102A0 (en) * 2002-06-25 2002-07-18 Drug Delivery Solutions Pty Ltd Transdermal aerosol compositions
US7704518B2 (en) * 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US20060018937A1 (en) * 2002-10-25 2006-01-26 Foamix Ltd. Steroid kit and foamable composition and uses thereof
CA2433101A1 (en) * 2003-06-23 2004-12-23 Igor Gonda Method of treatment of a female suffering from androgen insufficiency
US20070275943A1 (en) * 2003-11-19 2007-11-29 Acrux Dds Pty Ltd. Method and Composition for Treatment or Prophylaxis of Amyloidosis Disorders
US20080027033A1 (en) * 2003-11-19 2008-01-31 Acrux Dds Pty Ltd Method and Composition for Treatment of Cutaneous Lesions
UA85871C2 (uk) 2004-03-15 2009-03-10 Такеда Фармасьютікал Компані Лімітед Інгібітори дипептидилпептидази
JP4613622B2 (ja) * 2005-01-20 2011-01-19 住友電気工業株式会社 軟磁性材料および圧粉磁心
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
CN101223421A (zh) * 2005-05-18 2008-07-16 Gi公司 口服给药系统及其使用方法
EP1896038B1 (en) * 2005-06-03 2016-11-09 Acrux DDS Pty Ltd Method and composition for testosterone transdermal delivery
CN101212975A (zh) * 2005-06-03 2008-07-02 艾克若克斯Dds有限公司 用于透皮给药的方法和组合物
JP5584415B2 (ja) * 2005-10-12 2014-09-03 ユニメッド・ファーマシューティカルズ・エルエルシー 改良したテストステロンゲル製剤及び使用の方法
WO2008073684A1 (en) * 2006-12-08 2008-06-19 Lipo Chemicals Inc. Composition for treating aging skin comprising a hydroxycinnamic acid such as p-coumaric acid
EA201000747A1 (ru) * 2007-11-02 2010-10-29 АКРУКС ДиДиЭс ПиТиУай ЭлТиДи Система и способ трансдермальной доставки и способ получения системы трансдермальной доставки
JP5675175B2 (ja) * 2009-06-23 2015-02-25 大陽日酸株式会社 オゾン供給装置

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044347A1 (en) * 1999-02-01 2000-08-03 Cipla Limited Medicated stick composition
WO2006113242A2 (en) * 2005-04-13 2006-10-26 Unimed Pharmaceuticals, Inc. Method of increasing testosterone and related steroid concentrations in women
JP2008536851A (ja) * 2005-04-13 2008-09-11 ユニメド ファーマスーティカルズ インク 女性でテストステロンおよび関連ステロイドの濃度を増加させる方法
WO2007016766A1 (en) * 2005-08-05 2007-02-15 Nuvo Research Inc. Transdermal drug delivery formulation

Also Published As

Publication number Publication date
EP2214643A1 (en) 2010-08-11
KR101662186B1 (ko) 2016-10-04
PL2219603T3 (pl) 2014-10-31
CN101888830A (zh) 2010-11-17
AU2008318283A1 (en) 2009-05-07
WO2009055860A1 (en) 2009-05-07
HK1143091A1 (en) 2011-03-18
CN101883556B (zh) 2013-05-29
US20130317122A1 (en) 2013-11-28
JP5737942B2 (ja) 2015-06-17
NZ585033A (en) 2011-12-22
US20160022820A1 (en) 2016-01-28
PT2219603E (pt) 2014-09-02
CA2704117A1 (en) 2009-05-07
CA2704117C (en) 2015-11-17
EP2219603A4 (en) 2010-11-17
EA019760B1 (ru) 2014-06-30
CN101888830B (zh) 2013-01-23
EA201000747A1 (ru) 2010-10-29
DK2219603T3 (da) 2014-09-01
ZA201003553B (en) 2011-02-23
CN101883556A (zh) 2010-11-10
ES2466676T3 (es) 2014-06-10
ES2494853T3 (es) 2014-09-16
US20130317462A1 (en) 2013-11-28
AU2008318284A1 (en) 2009-05-07
DK2214643T3 (da) 2014-05-26
EP2219603A1 (en) 2010-08-25
AU2008318283B2 (en) 2012-03-29
MX2010004789A (es) 2010-07-05
KR20100094495A (ko) 2010-08-26
CA2704116A1 (en) 2009-05-07
HK1144375A1 (en) 2011-02-18
KR20100094983A (ko) 2010-08-27
US9078810B2 (en) 2015-07-14
EP2219603B1 (en) 2014-07-16
PT2214643E (pt) 2014-05-26
JP2011502173A (ja) 2011-01-20
US20100279988A1 (en) 2010-11-04
AU2008318284B2 (en) 2012-03-22
EP2214643B1 (en) 2014-04-02
US20100297032A1 (en) 2010-11-25
BRPI0819245A2 (pt) 2016-07-19
EP2214643A4 (en) 2010-12-01
PL2214643T3 (pl) 2014-09-30
EA201000746A1 (ru) 2010-10-29
BRPI0819235A2 (pt) 2017-08-22
MX2010004788A (es) 2010-09-14
NZ585034A (en) 2011-08-26
WO2009055859A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
AU2008318283B2 (en) Transdermal delivery system for hormones and steroids
EP0971705B1 (en) Hormone replacement therapy drug formulations for topical application to the skin
Hadgraft et al. Transdermal delivery of testosterone
HK1143091B (en) Transdermal delivery system for hormones and steroids
CA2919648C (en) Natural solubilizer agent comprising a synergistic blend of heptyl glucoside and olive oil glycereth-8 esters for transdermal compositions
HK1144375B (en) Transdermal delivery system

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20111021

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20111021

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130625

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130924

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131001

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131024

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20140701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20140930

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20141007

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141028

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20150512

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20150929